New hope for tough pancreatic cancer? drug combo targets KRAS mutations

NCT ID NCT07640295

Not yet recruiting Disease control Sponsor: Jacobio Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called JAB-23E73, which targets KRAS gene changes, combined with two standard chemotherapies (nab-paclitaxel and gemcitabine) in people whose pancreatic cancer has spread and who haven't had prior treatment. The goal is to see if the combination is safe and shrinks tumors. About 80 participants will take part in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JAB-23E73 (a pan KRAS inhibitor) combined with nab-paclitaxel and gemcitabine chemotherapy
What this could lead to: If successful, this could offer a new treatment option for people with a hard-to-treat form of pancreatic cancer that has spread.
What could go wrong: This is an early-phase trial with only 80 participants, so results may not apply to everyone. The drug combination may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Beijing Tsinghua Changgung Hospital

Beijing, China
Harbin Medical University Cancer Hospital

Harbin, China
Henan Cancer Hospital

Zhengzhou, China
Hubei Province Hospital

Wuhan, China
Hunan Cancer Hospital

Changsha, China
Jiangsu Province Hospital

Nanjing, China
ShanXi Cancer Hospital

Taiyuan, China
Shanghai Jiaotong University School of Medicine Ruijin Hospital

Shanghai, China
The First Affiliated hospital of Zhengzhou University

Zhengzhou, China
Wuhan Union Hospital Of China

Wuhan, China
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, 310005, China
Zhongnan Hospital of Wuhan University

Wuhan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.